NCT04790682Recruiting
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer
Source: ClinicalTrials.gov · Last updated 18 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 5 Mar 2021
- Start date
- 22 May 2021
- Primary completion date
- 3 Jun 2029
- Lead sponsor
- Institut Curie
- Diseases
- Lung cancer
- NCT number
- NCT04790682
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 22 May 2021 to the primary completion date, 3 Jun 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnant and breastfeeding women.
- Patients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's information
Other
- No social security affiliation.
- Person under legal protection.
Who the study is looking for
- Histologically-proven NSCLC.
- Age ≥ 18 years.
- Advanced or metastatic stage IV.
- Treatment-naïve patient.
- Eligibility to first-line treatment with immune checkpoint inhibitor.
- Measurable disease according to RECIST 1.1 criteria on CT-Scan.
- Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.
- No ALK or EGFR gene alteration.
- Availability of tumor tissue for NGS analysis (7 slides).
- PS 0 or 1.
- Signed informed consent of the patient.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Ambroise-Paré Coordinator of this site? Confirm its status | Boulogne-Billancourt | France | Recruiting |
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| Institut Curie Coordinator of this site? Confirm its status | Saint-Cloud | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.